Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1851845rdf:typepubmed:Citationlld:pubmed
pubmed-article:1851845lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:1851845lifeskim:mentionsumls-concept:C0597358lld:lifeskim
pubmed-article:1851845lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:1851845lifeskim:mentionsumls-concept:C0243076lld:lifeskim
pubmed-article:1851845lifeskim:mentionsumls-concept:C1883712lld:lifeskim
pubmed-article:1851845lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:1851845lifeskim:mentionsumls-concept:C0205549lld:lifeskim
pubmed-article:1851845lifeskim:mentionsumls-concept:C2349975lld:lifeskim
pubmed-article:1851845lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:1851845lifeskim:mentionsumls-concept:C0125642lld:lifeskim
pubmed-article:1851845lifeskim:mentionsumls-concept:C0205198lld:lifeskim
pubmed-article:1851845pubmed:issue5lld:pubmed
pubmed-article:1851845pubmed:dateCreated1991-6-26lld:pubmed
pubmed-article:1851845pubmed:abstractTextThe combination of the benzopyran-4-one ring, a moiety found in the prototype leukotriene antagonist, FPL 55,712, with the (2-quinolinylmethoxy)phenyl group led to a significant increase in leukotriene receptor binding affinity. This modification resulted in a 10,000-fold improvement in binding affinity compared to FPL 55,712. Compound 7 (RG 12553), with a Ki value of 0.1 nM, has higher affinity than the natural agonist LTD4 and is one of the most potent LTD4 antagonists reported. The structure-activity relationships of this series of potent leukotriene antagonists are discussed.lld:pubmed
pubmed-article:1851845pubmed:languageenglld:pubmed
pubmed-article:1851845pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1851845pubmed:citationSubsetIMlld:pubmed
pubmed-article:1851845pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1851845pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1851845pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1851845pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1851845pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1851845pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1851845pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1851845pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1851845pubmed:statusMEDLINElld:pubmed
pubmed-article:1851845pubmed:monthMaylld:pubmed
pubmed-article:1851845pubmed:issn0022-2623lld:pubmed
pubmed-article:1851845pubmed:authorpubmed-author:HuangF CFClld:pubmed
pubmed-article:1851845pubmed:authorpubmed-author:VanInwegenR...lld:pubmed
pubmed-article:1851845pubmed:authorpubmed-author:CampbellH FHFlld:pubmed
pubmed-article:1851845pubmed:authorpubmed-author:MorrissetteM...lld:pubmed
pubmed-article:1851845pubmed:authorpubmed-author:JohnsonW...lld:pubmed
pubmed-article:1851845pubmed:authorpubmed-author:CarnathanG...lld:pubmed
pubmed-article:1851845pubmed:authorpubmed-author:LearyK JKJlld:pubmed
pubmed-article:1851845pubmed:authorpubmed-author:GalemmoR...lld:pubmed
pubmed-article:1851845pubmed:authorpubmed-author:PoliG BGBlld:pubmed
pubmed-article:1851845pubmed:authorpubmed-author:DankulichW...lld:pubmed
pubmed-article:1851845pubmed:issnTypePrintlld:pubmed
pubmed-article:1851845pubmed:volume34lld:pubmed
pubmed-article:1851845pubmed:ownerNLMlld:pubmed
pubmed-article:1851845pubmed:authorsCompleteYlld:pubmed
pubmed-article:1851845pubmed:pagination1704-7lld:pubmed
pubmed-article:1851845pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:meshHeadingpubmed-meshheading:1851845-...lld:pubmed
pubmed-article:1851845pubmed:year1991lld:pubmed
pubmed-article:1851845pubmed:articleTitleDevelopment of a novel series of (2-quinolinylmethoxy)phenyl-containing compounds as high-affinity leukotriene D4 receptor antagonists. 4. Addition of chromone moiety enhances leukotriene D4 receptor binding affinity.lld:pubmed
pubmed-article:1851845pubmed:affiliationRhone-Poulenc Rorer Central Research, King of Prussia, Pennsylvania 19406.lld:pubmed
pubmed-article:1851845pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:1851845lld:chembl